ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011
Integrating pain metrics into oncology clinical trials.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.Neurology · 2016Guideline
- Crosswalk between PROMIS computer adaptive tests and numerical rating scales in cancer patients: Anxiety, depression, pain interference, physical function.Advances in patient-reported outcomes · 2025Article
- NCI's publication affiliation conundrum: Reframing innovation to incentivize an equitable path for advocate representation.Translational oncology · 2022Article
- Pain prevalence and treatment in patients with metastatic bone disease.Oncology letters · 2019Article
- CORR Insights®: Early Improvement in Pain and Functional Outcome but Not Quality of Life After Surgery for Metastatic Long Bone Disease.Clinical orthopaedics and related research · 2018Article
- An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Article
- Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model.European journal of pharmacology · 2014Article
- Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2013Article
- Translational approaches to treatment-induced symptoms in cancer patients.Nature reviews. Clinical oncology · 2012Review
- Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-related pain is highly prevalent and often severe, and as a result is often one of the defining experiences for patients with malignancy. Patients and patients' families almost always live with the ever-present reality that cancer treatment and progression may be accompanied by pain. For patients nearing the end of life, most fear that their final days will be spent living with the terrible effects of the disease, the most important of which is pain. Despite this, there is far less systematic research on the mechanisms of cancer-related pain or on the development of new agents to reduce or eliminate pain in cancer patients compared with research to combat the disease itself. Further, even when the focus of research is treatment of the tumor, the effects of anticancer treatments on pain are often underreported in publications and other forums. To illustrate the relative drought in the cancer pain control area, there have been no new drugs approved for cancer-related pain in recent years. A number of methodologic and logistical challenges that hinder the ability to assess pain response in clinical trials are discussed in this article. Possible ways to address these challenges are also discussed.
Indexed as
Identifiers
22046026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.